Platelet hyperprocoagulant activity in Type 2 diabetes mellitus: Attenuation by glycoprotein IIb/IIIa inhibition

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 12, 2008, Pages 2186-2192

  Razmara, M ^a   Hjemdahl, P ^a   Ostenson C G ^a   Li, Nailin ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Coagulation; GPIIb IIIa inhibitor; Platelets; Type 2 diabetes mellitus

Indexed keywords

3 [[4 [4 (AMINOIMINOMETHYL)PHENYL] 2 THIAZOLYL](1 CARBOXYMETHYL 4 PIPERIDINYL)AMINO]PROPIONIC ACID; BLOOD CLOTTING FACTOR 5A; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEMOGLOBIN A1C; PHOSPHATIDYLSERINE;

ADULT; ANTICOAGULATION; ARTICLE; BINDING AFFINITY; BLOOD CLOTTING TIME; BLOOD FLOW; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOLOGICAL BLOCKING; PLATELET MICROPARTICLE; PRIORITY JOURNAL; THROMBIN TIME; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA;

BENZYLAMINES; BLOOD PLATELETS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; HUMANS; PHOSPHATIDYLSERINES; PIPERIDINES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECEPTORS, THROMBIN; THIAZOLES; THROMBOPHILIA;

EID: 56749096773     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03185.x     Document Type: Article

References (30)

1. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in Type 2 diabetes. Diabetes Care 2001; 24: 1476-85.
2. Colwell JA, Nesto RW. The platelet in diabetes: Focus on prevention of ischemic events. Diabetes Care 2003; 26: 2181-8.
3. Ferroni P, Basili S, Falco A, Davi G. Platelet activation in Type 2 diabetes mellitus. J Thromb Haemost 2004; 2: 1282-91.
4. Hu H, Li N, Yngen M, Östenson C-G, Wallén NH, Hjemdahl P. Enhanced leukocyte-platelet cross-talk in Type 1 diabetes mellitus: relationship to microangiopathy. J Thromb Haemost 2004; 2: 58-64.
5. Yngen M, Östenson CG, Hu H, Li N, Hjemdahl P, Wallén NH. Enhanced P-selectin expression and increased soluble CD40 ligand in patients with Type 1 diabetes mellitus and microangiopathy: Evidence for platelet hyperactivity and chronic inflammation. Diabetologia 2004; 47: 537-40.
6. Lupu C, Calb M, Ionescu M, Lupu F. Enhanced prothrombin and intrinsic factor X activation on blood platelets from diabetic patients. Thromb Haemost 1993; 70: 579-83.
7. Boden G, Rao AK. Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation. Curr Diab Rep 2007; 7: 223-7.
8. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570-81.
9. Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003; 108: 1527-32.
10. Quinn MJ, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword? Circulation 2002; 106: 379-85.
11. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C, Hamm CW, Moliterno DJ, Califf RM, White HD, Kleiman NS, Theroux P, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2001; 104: 2767-71.
12. Lincoff AM. Important triad in cardiovascular medicine: Diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa receptor blockade. Circulation 2003; 107: 1556-9.
13. Mehilli J, Kastrati A, Schuhlen H, Dibra A, Dotzer F, von Beckerath N, Bollwein H, Pache J, Dirschinger J, Berger PP, Schomig A. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004; 110: 3627-35.
14. Furman MI, Krueger LA, Frelinger AL, Barnard MR, Mascelli MA, Nakada MT, Michelson AD. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood. Thromb Haemost 2000; 84: 492-8.
15. Razmara M, Hu H, Masquelier M, Li N. Glycoprotein IIb/IIIa blockade inhibits platelet aminophospholipid exposure by potentiating translocase and attenuating scramblase activity. Cell Mol Life Sci 2007; 64: 999-1008.
16. Reverter JC, Béguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. J Clin Invest 1996; 98: 863-74.
17. Li N, Wallèn NH, Savi P, Hèrault JP, Herbert JM. Effects of a new platelet glycoprotein IIb/IIIa antagonist, SR121566, on platelet activation, platelet-leukocyte interaction and thrombin generation. Blood Coagul Fibrinol 1998; 9: 507-15.
18. Gibson CM, de Lemos JA, Murphy SA, Marble SJ, McCabe CH, Cannon CP, Antman EM, Braunwald E. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: A TIMI 14 substudy. Circulation 2001; 103: 2550-4.
19. Mousa SA, Khurana S, Forsythe MS. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: Differentiation among glycoprotein IIb/IIIa antagonists. Arterioscler Thromb Vasc Biol 2000; 20: 1162-7.
20. Collet JP, Montalescot G, Lesty C, Weisel JW. A structural and dynamic investigation of the facilitating effect of glycoprotein IIb/IIIa inhibitors in dissolving platelet-rich clots. Circ Res 2002; 90: 428-34.
21. Li N, Hu H, Lindqvist M, Wikström-Jonsson E, Goodall AH, Hjemdahl P. Platelet-leukocyte cross-talk in whole blood. Arterioscl Thromb Vasc Biol 2000; 20: 2702-8.
22. Hu H, Zhang W, Li N. Glycoprotein IIb/IIIa inhibition attenuates platelet-activating factor-induced platelet activation by reducing protein kinase C activity. J Thromb Haemost 2003; 1: 1805-12.
23. Yngen M, Östenson C-G, Hjemdahl P, Wallén NH. Meal-induced platelet activation in Type 2 diabetes mellitus: Effects of treatment with repaglinide and glibenclamide. Diabet Med 2006; 23: 134-40.
24. Tang WH, Lincoff AM. Diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa blockade: The triad revisited. Circulation 2004; 110: 3618-20.
25. Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: A meta-analysis of phase III multicenter randomized trials. Circulation 2001; 103: 201-6.
26. Peter K, Schwarz M, Ylanne J, Kohler B, Moser M, Nordt T, Salbach P, Kubler W, Bode C. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors. Blood 1998; 92: 3240-9.
27. Pedicord DL, Thomas BE, Mousa SA, Dicker IB. Glycoprotein IIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity. Thromb Res 1998; 90: 247-58.
28. Keularts IM, Beguin S, de Zwaan C, Hemker HC. Treatment with a GPIIb/ IIIa antagonist inhibits thrombin generation in platelet-rich plasma from patients. Thromb Haemost 1998; 80: 370-1.
29. Moliterno DJ, Califf RM, Aguirre FV, Anderson K, Sigmon KN, Weisman HF, Topol EJ. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol 1995; 75: 559-62.
30. Gemmell CH, Sefton MV, Yeo EL. Platelet-derived microparticle formation involves glycoprotein IIb-IIIa. Inhibition by RGDS and a Glanzmann's thrombasthenia defect. J Biol Chem 1993; 268: 14586-9.